The global burden of hepatocellular carcinoma (HCC) is increasing and might soon surpass
an annual incidence of 1 million cases. Genomic studies have established the landscape of …

Abstract RAS mutations (HRAS, NRAS, and KRAS) are among the most common
oncogenes, and around 19% of patients with cancer harbor RAS mutations. Cells harboring …

Hepatocellular carcinoma (HCC) has emerged as a major cause of cancer-related death. Its
mortality has increased in Western populations, with a minority of patients diagnosed at …

Mortality owing to liver cancer has increased in the past 20 years, and the latest estimates
indicate that the global health burden of this disease will continue to grow. Most patients with …

The current development status of mitogen-activated protein kinase kinase (MEK) inhibitors,
including the preclinical data and clinical study progress, has been summarized in this …

Sorafenib, an orally-available kinase inhibitor, is the only standard clinical treatment against
advanced hepatocellular carcinoma. However, development of resistance to sorafenib has …

Hepatocellular carcinoma (HCC) is the most common primary tumor of the liver. Its
relationship to chronic liver diseases, in particular cirrhosis, develops on a background of …

Background The approval of the tyrosine kinase inhibitor sorafenib in 2007 marked a
milestone in the treatment of hepatocellular carcinoma, as sorafenib was the first systemic …

Despite the recent introduction of new effective systemic agents, the survival of patients with
hepatocellular carcinoma (HCC) at advanced stages remains dismal. This underscores the …

Systemic therapy for hepatocellular carcinoma (HCC) changed drastically after the
introduction of the molecular targeted agent sorafenib in 2007. Sorafenib provides an …